Skip to main content

Table 2 Subgourp analyses of EFS on TET2 mutation

From: The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis

Variables

Number of studies, heterogeneity I2%, p

Pooled HRs(95% CI), P value

Interaction(p)

Year

2016

1

3.430[1.479–7.955], P = 0.004

0.096

2015

3(74.8), P = 0.019

1.320[0.911–1.913], P = 0.142

2014

1

0.800[0.327–1.955], P = 0.624

2012

2(1.7), P = 0.313

1.613[1.217–2.138], P = 0.001

2011

1

1.320[0.982–1.774], P = 0.066

2010

1

3.970[1.140–13.826], P = 0.030

Data type

Multivariate

3(76.4), P = 0.014

1.284[0.891–1.850], P = 0.181

0.110

Calculated from K-M curves

5(26.2), P = 0.247

1.473[1.209–1.794], P < 0.001

univariate

1

3.430[1.479–7.955], P = 0.004

Region

America

2(83.0), P = 0.015

1.479[1.117–1.959], P = 0.006

0.413

Europe

4(44.1), P = 0.147

1.580[1.215–2.055], P = 0.001

Asia

2(76.4), P = 0.040

1.934[1.020–3.667], P = 0.043

other

1

1.076[0.688–1.682], P = 0.748

Cohort

AML

2(79.4), P = 0.028

1.669[1.189–2.344], P = 0.003

0.444

CN-AML

5(47.5), P = 0.106

1.377[1.120–1.692], P = 0.002

Others

2(76.4), P = 0.040

1.934[1.020–3.667], P = 0.043

Detection methods

Direct sequencing

6(13.1), P = 0.331

1.283[1.058–1.556], P = 0.011

0.002

Next-generation sequencing

3(38.3), P = 0.198

2.418[1.691–3.459], P < 0.001

  1. Abbreviations: HRs hazard ratios, CN-AML cytogenetically normal acute myeloid leukemia